BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Frequently asked questions
What sector does BlossomHill Therapeutics, Inc. Common Stock (BLSM) operate in?
BlossomHill Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BlossomHill Therapeutics, Inc. Common Stock (BLSM) current stock price?
As of the latest data, BlossomHill Therapeutics, Inc. Common Stock stock price is $16.39, with a previous close of $14.63. BlossomHill Therapeutics, Inc. Common Stock gained $1.76 in the last trading session, representing a 12.03% increase.
What is BlossomHill Therapeutics, Inc. Common Stock (BLSM) current market capitalization?
BlossomHill Therapeutics, Inc. Common Stock market cap is approximately 476.64 million.
What is BlossomHill Therapeutics, Inc. Common Stock (BLSM) Earnings Per Share (EPS)?
The trailing EPS is -$3.48, and the forward EPS is -$3.71.
What is BlossomHill Therapeutics, Inc. Common Stock (BLSM) EBITDA?
BlossomHill Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -21.98 million.
Does BlossomHill Therapeutics, Inc. Common Stock (BLSM) pay dividends?
No. BlossomHill Therapeutics, Inc. Common Stock does not pay a dividend.
What is BlossomHill Therapeutics, Inc. Common Stock (BLSM) beta (volatility) score?
BlossomHill Therapeutics, Inc. Common Stock has a beta of -0.052, indicating lower volatility than the overall market.
